Oxford BioMedica PLC OXO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- €5.85
- Day Range
- €5.80–6.35
- 52-Week Range
- €3.98–19.10
- Bid/Ask
- €6.20 / €6.65
- Shares Outstanding
- 121.05M
- Market Cap
- £762.61M
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 3.47
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Oxford BioMedica PLC is a contract development and manufacturing organization (CDMO) focused on cell and gene therapy. The company specializes in viral vector development and manufacturing for cell and gene therapy, with expertise in lentivirus, adeno-associated virus (AAV), adenovirus, and other viral vector types. Geographically, it derives maximum revenue from the United States, and the rest from Europe, the UK, and the Rest of the world.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 986
- Website
- https://www.oxb.com
Valuation
|
Metric
|
OXO
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 10.50 |
Price/Sales | 3.47 |
Price/Cash Flow | — |
Price/Earnings
OXO
Financial Strength
|
Metric
|
OXO
|
|---|---|
Quick Ratio | 1.76 |
Current Ratio | 2.21 |
Interest Coverage | −2.05 |
Quick Ratio
OXO
Profitability
|
Metric
|
OXO
|
|---|---|
Return on Assets (Normalized) | −13.55% |
Return on Equity (Normalized) | −62.55% |
Return on Invested Capital (Normalized) | −14.37% |
Return on Assets
OXO
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|y?G^z@J | LOCK|>S#&X | $128B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|sRXfHp^ | LOCK|N>X<< | $76B | |||
| Moderna Inc
MRNA
| LOCK|Z!@<k$ | LOCK|^fP | $75B | |||
| argenx SE ADR
ARGX
| LOCK|FhdLs&! | LOCK|N$^ | $60B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|!S?w$<w | LOCK|%s$ | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|$$>>HN | LOCK|!%qJ& | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|&#&zQh#C | LOCK|TZ$M | $26B | |||
| BioNTech SE ADR
BNTX
| LOCK|MtZW>J# | LOCK|nw | $24B | |||
| Incyte Corp
INCY
| LOCK|!qSF>^ | LOCK|Dq | $24B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|tF<^nhX | LOCK|<< | $15B |
United States